Cost-effectiveness of bevacizumab for diabetic macular oedema

Abstract

A Markov model was developed to predict the outcomes and cost-effectiveness of bevacizumab compared to macular laser therapy for diabetes patients with clinically significant macular oedema (CSMO). This study used outcome data from a randomised controlled trial, utility data and health states from a ranibizumab health technology assessment, and costs from the UK national tariff. A total of 37.73% of patients treated with bevacizumab in the model had a visual acuity of at least 76 Early Treatment Diabetic Retinopathy Study Research Group (ETDRS) letters after four years, compared with 4.09% of laser therapy patients. Only 0.11% of bevacizumab patients were blind after four years compared with 6.45% of laser therapy patients. However, with an incremental cost-effectiveness ratio of £51,182, we predict that bevacizumab would not be cost-effective compared to laser therapy because of the influence of the NHS national tariff costs for monitoring patients and administering bevacizumab, and the inability of the EQ-5D measure to capture the impact of sensory deprivation on quality of life sufficiently. This study recommends significant caution when interpreting the results of cost-effectiveness analyses of interventions that involve vision-related interventions.